3,3-dimethyl-1-tosylazetidine | 79201-18-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3,3-dimethyl-1-tosylazetidine
• 英文别名: 1-(p-toluenesulfonyl)-3,3-dimethylazetidine；3,3-dimethyl-1-(4-methylphenyl)sulfonylazetidine
• CAS: 79201-18-6
• 化学式: C₁₂H₁₇NO₂S
• 分子量: 239.338
• InChiKey: CMICGHINXUADPK-UHFFFAOYSA-N

物化性质

• 熔点：
  62-64 °C(Solv: methanol (67-56-1); water (7732-18-5))
• 沸点：
  342.9±35.0 °C(Predicted)
• 密度：
  1.173±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  45.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3,3-dimethyl-1-tosylazetidine 在 magnesium 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 20.5h， 生成 3,3-dimethyl-1-(phenylmethyl)azetidine
  参考文献：
  名称：

  使用氮杂环丁烷转化动力学研究硼-氮键。

  摘要：

  报道了一种探测BN双键强度的方法。已通过VT-NMR定量了一系列与硼酸酯连接的氮杂环丁烷中氮转化的活化参数，测得的势垒与通过（11）B NMR，X射线晶体学和MP2计算获得的数据相关。

  DOI：

  10.1039/c3cc36159d
• 作为产物：
  描述：

  二甲基丙二酸二乙酯 在 lithium aluminium tetrahydride 、 potassium carbonate 、 三乙胺 、 potassium iodide 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成 3,3-dimethyl-1-tosylazetidine
  参考文献：
  名称：

  9-AMINOMETHYL SUBSTITUTED TETRACYCLINE COMPOUNDS

  摘要：

  公开号：

  EP2738156B1

文献信息

• Site‐Specific Alkene Hydromethylation via Protonolysis of Titanacyclobutanes
  作者：James A. Law、Noah M. Bartfield、James H. Frederich

  DOI：10.1002/anie.202103278

  日期：2021.6.21

  Methyl groups are ubiquitous in biologically active molecules. Thus, new tactics to introduce this alkyl fragment into polyfunctional structures are of significant interest. With this goal in mind, a direct method for the Markovnikov hydromethylation of alkenes is reported. This method exploits the degenerate metathesis reaction between the titanium methylidene unveiled from Cp2Ti(μ-Cl)(μ-CH2)AlMe2

  甲基在生物活性分子中普遍存在。因此，将这种烷基片段引入多官能结构的新策略引起了人们的极大兴趣。考虑到这一目标，报告了一种烯烃马尔可夫尼科夫氢甲基化的直接方法。该方法利用了Cp 2 Ti(μ-Cl)(μ-CH 2 )AlMe 2 (Tebbe试剂)中的钛亚甲基与未活化的烯烃之间的简并复分解反应。所得环丁烷钛的原位质子解作用以化学、区域和位点选择性方式实现氢甲基化。该方法的广泛实用性在一系列含有侧醇、醚、酰胺、氨基甲酸酯和碱性胺的单取代和二取代烯烃中得到了证明。
• A Facile Syntehsis of 2-Substituted Azetidines
  作者：Tatsuya Shono、Yoshihiro Matsumura、Kenshi Uchida、Fumihiko Nakatani

  DOI：10.1246/bcsj.61.3029

  日期：1988.8

  A new method for the synthesis of 2-substituted azetidines has been exploited. The method consists of (1) anodic acetoxylation of 1-(p-tolylsulfonyl)azetidine at the 2-position and (2) subsequent nucleophilic substitution of the acetoxyl group with nucleophiles such as trimethylsilyl cyanide, allyltrimethylsilane, 2-acetoxyfuran, and trimethyl phosphite.

  开发了一种合成2-取代氮杂环丁烷的新方法。该方法包括 (1) 1-(对甲苯磺酰基)氮杂环丁烷在 2 位进行阳极乙酰氧基化，以及 (2) 随后用三甲基氰硅烷、烯丙基三甲基硅烷、2-乙酰氧基呋喃和亚磷酸三甲酯等亲核试剂对乙酰氧基进行亲核取代。
• 9-AMINOMETHYL SUBSTITUTED TETRACYCLINE COMPOUND
  申请人：KBP Biosciences Co., Ltd.

  公开号：EP2738156A1

  公开（公告）日：2014-06-04

  The present invention relates to 9-aminomethyl substituted tetracycline compounds represented by formula (I), or pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, as well as a method for preparing these compounds and a pharmaceutical composition comprising the same. The present invention relates also to a use of these compounds in the preparation of a medicament for the treatment and/or prophylaxis of tetracycline drug-sensitive disease. wherein, R2a, R2b, R3, R4a, R4b, R5, R6a, R6b, R7, R8, R9a, R9b, R10, R11, R12, R13a and R13b are each independently as defined in the description.

  本发明涉及由式(I)代表的9-氨甲基取代的四环素化合物，或其药学上可接受的盐、原药、溶媒或异构体，以及制备这些化合物和包含这些化合物的药物组合物的方法。本发明还涉及这些化合物在制备治疗和/或预防四环素药物敏感性疾病的药物中的用途。 其中，R2a、R2b、R3、R4a、R4b、R5、R6a、R6b、R7、R8、R9a、R9b、R10、R11、R12、R13a 和 R13b 各自独立地如描述中所定义。
• Froehlich, Johannes; Sauter, Fritz; Blasl, Karin, Heterocycles, 1994, vol. 37, # 3, p. 1879 - 1892
  作者：Froehlich, Johannes、Sauter, Fritz、Blasl, Karin

  DOI：——

  日期：——
• Novel Acetylcholine and Carbamoylcholine Analogues: Development of a Functionally Selective α₄β₂ Nicotinic Acetylcholine Receptor Agonist
  作者：Camilla P. Hansen、Anders A. Jensen、Jeppe K. Christensen、Thomas Balle、Tommy Liljefors、Bente Frølund

  DOI：10.1021/jm701625v

  日期：2008.12.11

  A series of carbamoylcholine and acetylcholine analogues were synthesized and characterized pharmacologically at neuronal nicotinic acetylcholine receptors (nAChRs). Several of the compounds displayed low nanomolar binding affinities to the alpha(4)beta(2) nAChR and pronounced selectivity for this subtype over alpha(3)beta(4), alpha(4)beta(4), and alpha(7) nAChRs. The high nAChR activity of carbamoylcholine analogue 5d was found to reside in its R-enantiomer, a characteristic most likely true for all other compounds in the series. Interestingly, the pronounced alpha(4)beta(2) selectivities exhibited by some of the compounds in the binding assays translated into functional selectivity. Compound 5a was a fairly potent partial alpha(4)beta(2) nAChR agonist with negligible activities at the alpha(3)beta(4) and alpha(7) subtypes, thus being one of the few truly functionally selective alpha(4)beta(2) nAChR agonists published to date. Ligand-protein docking experiments using homology models of the amino-terminal domains of alpha(4)beta(2) and alpha(3)beta(4) nAChRs identified residues Val 111(beta(2))/Ile 113(beta(4)), Phe 119(beta(2))/Gln 121(beta(4)), and Thr155(alpha(4))/Ser 150(alpha(3)) as possible key determinants of the alpha(4)beta(2)/alpha(3)beta(4)-selectivity displayed by the analogues. 4